(Dmytro “Henry” Aleksandrov, Headline USA) Big Pharma giants Pfizer wants the U.S. Food and Drug Administration to approve a first-of-its-kind vaccine that is reportedly supposed to protect infants from the respiratory syncytial virus, but only managed to pass half of it trial goals.
The Daily Wire reported that the Bivalent Prefusion F Vaccine is administered to expectant mothers during the second half of their pregnancy to protect infants against RSV.
The late-stage trial data showed that the experimental vaccine was 82% effective in preventing severe cases of the potentially deadly virus in infants 90 days after birth. However, the same trial data also showed that the numbers dropped to 69% efficacy in preventing severe infections up to 180 days after a baby is born. The new vaccine by Pfizer also failed to reduce non-severe illness in newborns.
